Table 1.
Laboratory indicators and clinical characteristics of healthy controls and patients with rheumatoid arthritis
| Characteristics | RA | HC |
|---|---|---|
| Number | 47 | 47 |
| Age (years)a | 57.13 ± 12.27 | 60.70 ± 10.89 |
| Sex (M/F) | 16/31 | 16/31 |
| Disease duration (month)b | 1008.00 (158.40, 1872.00) | NA |
| Anti-CCP (U/ml)a | 40.28 ± 15.20 | 32.34 ± 10.86 |
| DAS28* | 4.06 ± 1.14 | NA |
| CRP (mg/L)b | 25.14 (5.10, 73.40) | 3.1 (1.00, 42.65) |
| ESR (mm/h)a | 61.17 ± 34.13 | 33.12 ± 27.18 |
| ASO (µl/mL)b | 22.94 (11.60, 34.70) | NA |
| C3 (g/L)b | 1.29 (1.14, 1.50) | NA |
| C4 (g/L)a | 0.27 ± 0.06 | NA |
| Swollen jointsb | 6.00 (2.00, 10.00) | NA |
| Tender jointsb | 6.00 (3.00, 10.00) | NA |
| ILD positive (%) | 17.02% | NA |
In the groups providing PBMCs, there was no significant difference in age (p = 0.139, Student's t-test) and sex (p = 1.000, Chi-square) between RA patients and HC
RA, rheumatoid arthritis; HC, healthy controls; M/F, male/female; anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score in 28 joints; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ASO, antistreptolysin; C3, complement 3; C4, complement 4; ILD, interstitial lung disease; NA, not available
aExpressed as mean ± standard deviation
bExpressed as the median (25th to 75th percentile)